Objective:Essential requirements for successful gestation include the coordinated growth and differentiation of the placenta and the development of a functional placental vasculature. However, relatively little is known about factors that are responsible for regulating these functions. One angiogenic growth factor that might be involved in regulating both vascular endothelial cell and trophoblast function is placental growth factor (PGF).
Methods:Current published reports were surveyed and our own work was reviewed to highlight the expression, function, and potential significance of PGF at the human maternal-fetal interface.
Results:PGF is highly expressed in trophoblasts during normal pregnancy, and its expression is significantly decreased in preeclampsia, an obstetric complication presumed to be associated with placental bed hypoxia and ischemia. In agreement with this, in vitro trophoblast expression of PGF can be down-regulated by low oxygen tension. The cognate receptor for PGF, fms-like tyrosine kinase receptor, is expressed on trophoblasts as well as vascular endothelial cells, suggesting that it has autocrine and paracrine functions. Accordingly, PGF can regulate proliferation in first trimester trophoblasts, apoptosis in term trophoblasts, and it can directly or indirectly regulate vascular growth, maturation, and permeability.
Conclusion:Many obstetric complications, most notably preeclampsia, are associated with aberrant trophoblast function and inadequate or dysfunctional vasculature within the developing placenta. The ability of PGF to influence trophoblast and vascular endothelial cells provides clear impetus for further studies to investigate the biological and clinical significance of PGF in normal and abnormal human pregnancies.
1. Torry RJ, Schwartz JS, Torry DS. Vascularization of the placenta. In: Tomanek RJ, ed. Cardiovascular molecular morphogenesis: Assembly of the vasculature and its regulation. New York: Springer-Verlag, 2002:239-273.
2.
2. Klauber N, Rohan RM, Flynn E, D'Amato RJ. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med1997;3:443-446.
3.
3. Steingrimsson E, Tessarollo L, Reid SW, Jenkins NA, Copeland NG. The bHLH-Zip transcription factor Tfeb is essential for palcental avacularization. Development1998;125:4607-4616.
4.
4. Abbott BD, Buckalew AR. Placental defects in ARNT-knockout conceptus correlate with localized decreases in VEGF-R2, Ang-1, and Tie-2. Dev Dyn2000;219:526-538.
5.
5. Torry DS, Labarrere CA, McIntyre JA. Uteroplacental vascular involvement in recurrent spontaneous abortion. Curr Opin Obstet Gynecol1998;10:379-382.
6.
6. Kingdom JC, Kaufmann P. Oxygen and placental vascular development. Adv Exp Med Biol1999;474:259-275.
7.
7. Ong S, Lash G, Baker PN. Angiogenesis and placental growth in normal and compromised pregnancies. Baillieres Best Pract Res Clin Obstet Gynaecol2000;14:969-980.
8.
8. Kingdom J, Huppertz B, Seaward G, Kaufmann P. Development of the palcental villous tree and its consequences for fetal growth. Eur J Obstet Gynecol Reprod Biol2000;92:35-43.
9.
9. Reynolds LP, Redmer DA. Angiogenesis in the placenta. Biol Reprod2001;64:1033-1040.
10.
10. Maglione D, Guerriero V, Viglietto G, et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PGF), are transcribed from a single gene of chromosome 14. Oncogene1993;8:925-931.
11.
11. Iyer S, Leonidas DD, Swaminathan GJ, et al. The crystal structure of human palcenta growth factor-1 (PGF-1), an angiogenic protein, at 2.0 A resolution. J Biol Chem2001;276:12153-12161.
12.
12. Cao Y, Ji WR, Qi P, Rosin A. Placenta growth factor: Identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem Biophys Res Commun1997;235:493-498.
13.
13. Yang W, Ahn H, Hinrichs M, Torry RJ, Torry DS. Evidence of a novel isoform of placenta growth factor (PGF-4) expressed in human trophoblast and endothelial cells. J Reprod Immunol (In press).
14.
14. Hauser S, Weich HA. A heparin-binding form of placenta growth factor (PGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors1993;9:259-268.
15.
15. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem1994;269:25646-25654.
16.
16. Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for palcenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ1996;7:213-221.
17.
17. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol2001;33:409-420.
18.
18. Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR, Torry DS. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta1997;18:657-665.
19.
19. Vuckovic M, Ponting J, Terman BI, Niketic V, Seif MW, Kumar S. Expression of the vascular endothelial growth factor receptor, KDR, in human placenta. J Anat1996;188:361-366.
20.
20. Ahmed A, Li XF, Dunk C, Whittle MJ, Rushton DI, Rollason T. Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta. Growth Factors1995;12:235-243.
21.
21. Ishida A, Murray J, Saito Y, et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol2001;188:359-368.
22.
22. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood1996;87:3336-3343.
23.
23. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature1995;376:66-70.
24.
24. Hiratsuka S, Maru Y, Okada A, Seiki M, Noda T, Shibuya M. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res2001;61:1207-1213.
25.
25. Barleon B, Totzke F, Herzog C, et al. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem1997;272:10382-10388.
26.
26. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol1999;13:537-545.
27.
27. Clark DE, Smith SK, He Y, et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod1998;59:1540-1548.
28.
28. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A1998;95:8795-8800.
29.
29. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A1993;90:10705-10709.
30.
30. Banks RE, Forbes MA, Searles J, et al. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. Mol Hum Reprod1998;4:377-386.
31.
31. Ahmed A, Dunk C, Ahmad S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PGF) and soluble Flt-1 by oxygen: A review. Placenta2000;21:S16-S24.
32.
32. Migdal M, Huppertz B, Tessler S, et al. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem1998;273:22272-22278.
33.
33. Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins sema E and sema IV but not sema III. Neuron1997;19:547-559.
34.
34. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 es expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell1998;92:735-745.
35.
35. Lee P, Goishi K, Davidson AJ, Mannix R, Zon L, Klagsbrun M. Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc Natl Acad Sci U S A2002;99:10470-10475.
36.
36. Takashima S, Kitakaze M, Asakura M, et al. Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A2002;99:3657-3662.
37.
37. Matthies AM, Low QE, Lingen MW, DiPietro LA. Neuropilin-1 participates in wound angiogenesis. Am J Pathol2002;160:289-296.
38.
38. Zhang ZG, Tsang W, Zhang L, Powers C, Chopp M. Upregulation of neuropilin-1 in neovasculature after focal cerebral ischemia in the adult rat. J Cereb Blood Flow Metab2001;21:541-549.
39.
39. Miao HQ, Klagsbrun M. Neuropilin is a mediator of angiogenesis. Cancer Metastasis Rev2000;19:29-37.
40.
40. Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y. The neuropilins: Multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med2002;12:13-19.
41.
41. Gluzman-Poltorak Z, Cohen T, Shibuya M, Neufeld G. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem2001;276:18688-18694.
42.
42. Bernatchez PN, Rollin S, Soker S, Sirois MG. Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1. J Cell Biochem2002;85:629-639.
43.
43. Maglione D, Guerriero V, Viglietto G, Delli-Bovi P, Persico MG. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A1991;88:9267-9271.
44.
44. Clark DE, Smith SK, Licence D, Evans AL, Charnock-Jones DS. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol1998;159:459-467.
45.
45. Khaliq A, Li XF, Shams M, et al. Localisation of placenta growth factor (PIGF) in human term placenta. Growth Factors1996;13:243-250.
46.
46. Torry DS, Ahn H, Barnes EL, Torry RJ. Placenta growth factor: Potential role in pregnancy. Am J Reprod Immunol1999;41:79-85.
47.
47. Zhou Y, McMaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low paltelets syndrome. Am J Pathol2002;160:1405-1423.
48.
48. Yonekura H, Sakurai S, Liu X, et al. Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem1999;274:35172-35178.
49.
49. Tordjman R, Delaire S, Plouet J, et al. Erythroblasts are a source of angiogenic factors. Blood2001;97:1968-1974.
50.
50. Viglietto G, Romano A, Manzo G, et al. Upregulation of the angiogenic factors PGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene1997;15:2687-2698.
51.
51. Li XF, Charnock-Jones DS, Zhang E, et al. Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells. J Clin Endocrinol Metab2001;86:1823-1834.
52.
52. Failla CM, Odorisio T, Cianfarani F, Schietroma C, Puddu P, Zambruno G. Placenta growth factor is induced in human keratinocytes during wound healing. J Invest Dermatol2000;115:388-395.
53.
53. Takahashi A, Sasaki H, Kim SJ, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and palcenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res1994;54:4233-4237.
54.
54. Graeven U, Rodeck U, Karpinski S, Jost M, Andre N, Schmiegel W. Expression patterns of placenta growth factor in human melanocytic cell lines. J Invest Dermatol2000;115:118-123.
55.
55. Nomura M, Yamagishi S, Harada S, Yamashima T, Yamashita J, Yamamoto H. Placenta growth factor (PGF) mRNA expression in brain tumors. J Neurooncol1998;40:123-130.
56.
56. Donnini S, Machein MR, Plate KH, Weich HA. Expression and localization of placenta growth factor and PGF receptors in human meningiomas. J Pathol1999;189:66-71.
57.
57. Simpson DA, Murphy GM, Bhaduri T, Gardiner TA, Archer DB, Stitt AW. Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia. Biochem Biophys Res Commun1999;262:333-340.
58.
58. Khaliq A, Foreman D, Ahmed A, et al. Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest1998;78:109-116.
59.
59. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem1995;270:13333-13340.
60.
60. Marti HH, Risau W. Systemic hypoxia changes the organspecific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A1998;95:15809-15814.
61.
61. Gleadle JM, Ebert BL, Firth JD, Ratcliffe PJ. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol1995;268:C1362-C1368.
62.
62. Khaliq A, Dunk C, Jiang J, et al. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction upregulates placenta growth factor expression: Molecular evidence for “placental hyperoxia” in intrauterine growth restriction. Lab Invest1999;79:151-170.
63.
63. Green CJ, Lichtlen P, Huynh NT, et al. Placenta growth factor gene expression is induced by hypoxia in fibroblasts: a central role for metal transcription factor-1. Cancer Res2001;61:2696-2703.
64.
64. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and palsma extravasation in pathological conditions. Nat Med2001;7:575-583.
65.
65. Desai J, Holt-Shore V, Torry RJ, Caudle MR, Torry DS. Signal transduction and biological function of placenta growth factor in primary human trophoblast. Biol Reprod1999;60:887-892.
66.
66. Landgren E, Schiller P, Cao Y, Claesson-Welsh L. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene1998;16:359-367.
67.
67. Athanassiades A, Lala PK. Role of placenta growth factor (PIGF) in human extravillous trophoblast proliferation, migration and invasiveness. Placenta1998;19:465-473.
68.
68. Tibbles LA, Woodgett JR. The stress-activated protein kinase pathways. Cell Mol Life Sci1999;55:1230-1254.
69.
69. Leung DN, Smith SC, To KF, Sahota DS, Baker PN. Increased placental apoptosis in pregnancies complicated by preeclampsia. Am J Obstet Gynecol2001;184:1249-1250.
70.
70. Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ. Hypoxia-reoxygenation: A potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeeclampsia. Circ Res2002;90:1274-1281.
71.
71. Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol2002;186:158-166.
72.
72. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampaia. Am J Obstet Gynecol2000;183:1554-1557.
73.
73. Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol1998;179:1539-1544.
74.
74. Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol1999;106:1019-1022.
75.
75. Livingsto JC, Haddad B, Gorski LA, et al. Placenta growth factor is not an early marker for the development of severe preeclampsia. Am J Obstet Gynecol2001;184:1218-1220.
76.
76. Ziche M, Maglione D, Ribatti D, et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest1997;76:517-531.
77.
77. Eriksson A, Cao R, Pawliuk R, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PGF-1/VEGF heterodimers. Cancer Cell2002;1:99-108.
78.
78. Cao Y, Chen H, Zhou L, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem1996;271:3154-3162.
79.
79. Rahimi N, Dayanir V, Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J Biol Chem2000;275:16986-16992.
80.
80. Fong GH, rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature1995;376:66-70.
81.
81. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A1998;95:9349-9354.
82.
82. Li J, Brown LF, Hiberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol1996;270:H1803-H1811.
83.
83. DiSalvo J, Bayne ML, Conn G, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor. Placenta growth factor heterodimer. J Biol Chem1995;270:7717-7723.
84.
84. Barillari G, Albonici L, Franzese O, et al. The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into a soluble form: Implications for tumor angiogenesis. Am J Pathol1998;152:1161-1166.
85.
85. Kurz H, Wilting J, Sandau K, Christ B. Automated evaluation of angiogenic effects mediated by VEGF and PGF homo- and heterodimers. Microvasc Res1998;55:92-102.
86.
86. Khaliq A, Foreman D, Ahmed A, et al. Increased expression of placenta growth factor in proliferative diabetic. Lab Invest1998;78:109-116.
88. Torry DS, Torry RJ. Angiogenesis and the expression of vascular endothelial growth factor in endometrium and placenta. Am J Reprod Immunol1997;37:21-29.
89.
89. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med2002;8:831-840.
90.
90. Giordano FJ, Johnson RS. Angiogenesis: The role of the microenvironment in flipping the switch. Curr Opin Genet Dev2001;11:35-40.
91.
91. Murray MJ, Lessey BA. Embryo implantation and tumor metastasis: Common pathways of invasion and angiogenesis. Semin Reprod Endocrinol1999;17:275-290.
92.
92. Torry RJ, Rongish BJ. Angiogenesis in the uterus: Potential regulation and relation to tumor angiogenesis. Am J Reprod Immunol1992;27:171-179.
93.
93. Carmeliet P. VEGF gene therapy: Stimulating angiogenesis or angioma-genesis?Nat Med2000;6:1102-1103.
94.
94. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med2000;6:389-395.
95.
95. Deindl E, Buschmann I, Hoefer IE, et al. Role of ischemia and of hypoxia-inducible genes in arteriogenesis after femoral artery occlusion in the rabbit. Circ Res2001;89:779-786.
96.
96. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest1998;101:40-50.
97.
97. Clauss M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem1996;271:17629-17634.
98.
98. Parenti A, Brogelli L, Filippi S, Donnini S, Ledda F. Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: Role of flt-1/VEGF-receptor-1. Cardiovasc Res2002;55:201-212.
99.
99. Luttun A, Brusselmans K, Fukao H, et al. Loss of placental growth factor protects mice against vascular pemeability in pathological conditions. Biochem Biophys Res Commun2002;295:428-434.
100.
100. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top icrobiol Immunol1999;237:97-132.
101.
101. Adini A, Kornaga T, Firoozbakht F, Benjamin LE. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res2002;62:2749-2752.
102.
102. Genbacev O, Miller RK. Post-implantation differentiation and proliferation of cytotrophoblast cells: in vitro models—a review. Placenta2000;21(Suppl A):S45-S49.
103.
103. Su YN, Lee CN, Cheng WF, Shau WY, Chow SN, Hsieh FJ. Decreased maternal serum placenta growth factor in early second trimester and preeclampsia. Obstet Gynecol2001;97:898-904.
104.
104. Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH. First trimester maternal serum placenta growth factor (PIGF) concentrations in pregnancies with fetal trisomy 21 or trisomy 18. Prenat Diagn2001;21:718-722.
105.
105. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol2001;184:1267-1272.
106.
106. Tjoa ML, van Vugt JM, Mulders MA, Schutgens RB, Oudejans CB, van Wijk IJ. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol2001;98:600-607.
107.
107. Rajakumar A, Whitelock KA, Weissfeld LA, Daftary AR, Markovic N, Conrad KP. Selective overexpression of the hypoxia-inducible transcription factor, HIF-2alpha, in placentas from women with preeclampsia. Biol Reprod2001;64:499-506.
108.
108. Cooper JC, Sharkey AM, Charnock-Jones DS, Palmer CR, Smith SK. VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol1996;103:1191-1196.
109.
109. Lyall F, Greer IA, Boswell F, Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol1997;104:223-228.
110.
110. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W. Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood1999;94:1561-1567.
111.
111. Thornton RD, Lane P, borghaei RC, Pease EA, Caro J, Mochan E. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J2000;350:307-312.
112.
112. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Burgel T. Normoxic induction of the hypoxia-inducible factor lalpha by insulin and interleukin-1beta involves the phosphatidylinositol 3-kinase pathway. FEBS Lett2002;512:157-162.
113.
113. Levy R, Smith SD, Chandler K, Sadovsky Y, Nelson DM. Apoptosis in human cultured trophoblasts in enhanced by hypoxia and diminished by epidermal growth factor. Am J Physiol Cell Physiol2000;278:C982-C988.
114.
114. Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol1986;93:1049-1059.
115.
115. Caniggia I, Winter J, Lye SJ, Post M. Oxygen and placental development during the first trimester: Implications for the pathophysiology of pre-eclampsia. Placenta2000;21(Suppl A):S25-S30.
116.
116. Ong CY, Liao AW, Cacho AM, Spencer K, Nicolaides KH. First-trimester maternal serum levels of placenta growth factor as predictor of preeclampsia and fetal growth restriction. Obstet Gynecol2001;98:608-611.
117.
117. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem2001;47:617-623.
118.
118. Jauniaux E, Hustin J. Chromosomally abnormal early ongoing pregnancies: Correlation of ultrasound and placental histological findings. Hum Pathol1998;29:1195-1199.
119.
119. Frendo JL, Vidaud M, Guibourdenche J, et al. Defect of villous cytotrophoblast differentiation into syncytiotrophoblast in Donw's syndrome. J Clin Endocrimol Metab2000;85:3700-3707.
120.
120. Debieve F, Moiset A, Thomas K, Pampfer S, Hubinont C. Vascular endothelial growth factor and palcenta growth factor concentrations in Down's syndrome and control pregnancies. Mol Hum Reprod2001;7:765-770.
121.
121. Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Halmesmaki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod2001;7:205-210.
